0001437749-22-012464.txt : 20220516 0001437749-22-012464.hdr.sgml : 20220516 20220516073520 ACCESSION NUMBER: 0001437749-22-012464 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220516 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220516 DATE AS OF CHANGE: 20220516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACELRX PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001427925 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35068 FILM NUMBER: 22925505 BUSINESS ADDRESS: STREET 1: 25821 INDUSTRIAL BOULEVARD STREET 2: SUITE 400 CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: 650-216-3500 MAIL ADDRESS: STREET 1: 25821 INDUSTRIAL BOULEVARD STREET 2: SUITE 400 CITY: HAYWARD STATE: CA ZIP: 94545 8-K 1 acrx20220513_8k.htm FORM 8-K acrx20220513_8k.htm
false 0001427925 0001427925 2022-05-16 2022-05-16
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): May 16, 2022
 
ACELRX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 
 
Delaware
  
001-35068
  
41-2193603
(State of incorporation)
  
(Commission File No.)
  
(IRS Employer Identification No.)
 
25821 Industrial Boulevard, Suite 400
Hayward, CA 94545
(Address of principal executive offices and zip code)
 
Registrant’s telephone number, including area code: (650) 216-3500
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value
ACRX
The Nasdaq Global Market
 
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 2.02         Results of Operations and Financial Condition
 
On May 16, 2022, AcelRx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2022 and providing a corporate update (the “Release”). A copy of the Release is furnished herewith as Exhibit 99.1.
 
The information contained in this Item 2.02 and in Exhibit 99.1 shall be deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 2.02 and in Exhibit 99.1 shall not be incorporated by reference into any filing under the Securities Act or the Exchange Act made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
 
Item 9.01         Financial Statements and Exhibits
 
Exhibit No.
Description
99.1
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
1
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: May 16, 2022
ACELRX PHARMACEUTICALS, INC.
By:
/s/ Raffi Asadorian
Raffi Asadorian
Chief Financial Officer
         
2
 EX-99.1 2 ex_376053.htm EXHIBIT 99.1 ex_376053.htm

Exhibit 99.1

 

acelrx01.jpg
 
 

AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

 

Realigning cost structure from a focus on commercialization to a focus on development to advance late-stage pipeline; expected to result in annual savings of $9 million

 

Completed acquisition of Lowell Therapeutics and nafamostat franchise, including Niyad™ with Breakthrough Device Designation

 

Continued DSUVIA sales momentum with fourth consecutive quarter of sales volume growth, including 64% commercial (ex-DoD) growth in Q1 2022 compared to Q4 2021

 

$39.3 million of cash and short-term investments at March 31, 2022

 

Webcast and Conference Call to be held today at 8:30 am EDT

 

HAYWARD, Calif., May 16, 2022 – AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its first quarter 2022 financial results.

 

“DSUVIA continues to demonstrate solid sales growth and potential even with our limited commercial resources,” stated Vince Angotti, Chief Executive Officer of AcelRx. “We remain steadfast in our belief in DSUVIA’s value and its benefits to patients and healthcare providers with its unique pharmacokinetic characteristics, which are supported by favorable feedback received from physicians administering DSUVIA and numerous published studies. We believe that the uptake of this product will be maximized through a larger commercial infrastructure and, as such, we are in active discussions with potential partners that can execute a more robust commercial plan to support DSUVIA sales expansion, while further reducing AcelRx’s operating costs.”

 

Mr. Angotti continued, “Accordingly, we are aligning our cost structure to concentrate on our recently expanded development pipeline, which now includes our nafamostat portfolio and our pre-filled syringes. We believe these product candidates will provide multiple value-creating catalysts in the near-term, with two planned NDA submissions for the pre-filled syringes in 2022 and a potential emergency use authorization for Niyad in 2023. The reorganization of our corporate structure will drive shareholder value by extending our cash runway allowing us to continue progressing these development programs, remain focused on procedural suite sales and pursue further upside with a partner for DSUVIA.”

 

 
 

 

First Quarter and Recent Highlights

●

In May 2022, AcelRx reorganized to reduce headcount by approximately 40%, generating projected initial annual savings of $9 million.

 

●

AcelRx announced the closing of its acquisition of Lowell Therapeutics, Inc. (Lowell) in January 2022 in a transaction for consideration of approximately $32.5 million plus net cash acquired and certain other adjustments, and which includes up to approximately $26.0 million of contingent consideration payable in cash or stock at AcelRx’s option, upon the achievement of certain regulatory and sales-based milestones. Niyad™ (nafamostat) is the lead product, with a targeted indication of anticoagulation of the extracorporeal circuit, and which has received Breakthrough Device Designation from the FDA, as well as an ICD-10 procedural code from CMS which allows for reimbursement. Annual peak sales potential for Niyad is expected to exceed $200 million.

 

●

In May 2022, AcelRx hosted a key opinion leader webinar highlighting the market for and benefits of Niyad and LTX-608 with two internationally renowned acute kidney injury experts, Stuart Goldstein, MD, from Cincinnati Children’s Hospital, and Lakhmir Chawla, MD, former Chief of the Division of Intensive Care Medicine at the Washington D.C. Veterans Affairs Medical Center. https://www.acelrx.com/events/event-details/key-opinion-leader-kol-webinar-discuss-niyadtm-lyophilized-form-nafamostat

 

●

As of March 31, 2022, AcelRx has achieved 855 DSUVIA formulary approvals. As of April 30, 2022, AcelRx has achieved 893 formulary approvals for DSUVIA.

 

●

In the first quarter of 2022, AcelRx announced three publications, including: (1) a comparative data study between two different dialysis circuit anticoagulants in pediatric patients undergoing continuous renal replacement therapy (CRRT); (2) a study evaluating the use of a sufentanil sublingual tablet (SST) 30 mcg for management of pain of radiofrequency microneedling of the face or abdomen; and (3) a study evaluating real-world data in patients undergoing awake plastic surgery showing a rapid recovery time and minimal side effects with the use of SST for pain management.

 

●

In March 2022, AcelRx received a close-out letter from the U.S. Food and Drug Administration (FDA) confirming that it had concluded its evaluation of the Company’s corrective actions in response to the Warning Letter and that the Company had addressed the issues raised by the FDA Warning Letter dated February 11, 2021 regarding certain DSUVIA promotional materials.

 

 

Financial Information

 

●

The cash, cash equivalents and short-term investments balance was $39.3 million as of March 31, 2022.

 

●

First quarter 2022 net revenues were $0.4 million. DSUVIA units sold in the first quarter of 2022 were 10,530, compared to 8,960 units in the fourth quarter of 2021, reflecting unit sales growth of 18% from the prior quarter. Excluding fluctuating DoD revenues, unit sales growth was 64% in the first quarter of 2022 from the fourth quarter of 2021.

 

●

Combined R&D and SG&A expenses for the first quarter of 2022 totaled $8.7 million compared to $8.6 million for the first quarter of 2021. Excluding non-cash depreciation and stock-based compensation expense, these amounts were $7.7 million for the first quarter of 2022, compared to $7.4 million for the first quarter of 2021. The increase in combined R&D and SG&A expenses in the first quarter of 2022 was primarily due to increased DSUVIA manufacturing-related costs, partially offset by reductions in personnel-related expenses.

 

●

Net loss for the first quarter of 2021 was $8.7 million, or $0.06 per basic and diluted share, compared to $9.0 million, or $0.08 per basic and diluted share, for the first quarter of 2021.

 

 
 

 

Webcast and Conference Call Information

As previously announced, AcelRx will host a live webcast Monday, May 16th at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss these financial results and provide other corporate updates. The webcast is accessible by visiting the Investors page of AcelRx's website at www.acelrx.com and clicking on the webcast link. The webcast will be accompanied by a slide presentation. Investors who wish to participate in the conference call may do so by dialing (866) 361-2335 for domestic callers, (855) 669-9657 for Canadian callers or (412) 902-4204 for international callers. A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investor page of AcelRx’s website at www.acelrx.com.

 

About DSUVIA (sufentanil sublingual tablet), 30 mcg
DSUVIA®, known as DZUVEO® in Europe, is indicated for use in adults in certified medically supervised healthcare settings, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. DSUVIA was designed to provide rapid analgesia via a non-invasive route and to eliminate dosing errors associated with intravenous (IV) administration. DSUVIA is a single-strength solid dosage form administered sublingually via a single-dose applicator (SDA) by healthcare professionals. Sufentanil is an opioid analgesic previously only marketed for IV and epidural anesthesia and analgesia. The sufentanil pharmacokinetic profile, when delivered sublingually, avoids the high peak plasma levels and short duration of action observed with IV administration. DZUVEO has been approved by the European Medicines Agency and AcelRx's European commercialization partner, Aguettant, will market the drug in Europe.

 

This release is intended for investors only. For more information, including important safety information and black box warning for DSUVIA, please visit www.DSUVIA.com.

 

About nafamostat
Nafamostat is a broad spectrum, synthetic serine protease inhibitor with anticoagulant, anti-inflamatory and potential anti-viral activities. Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation Status from the FDA. LTX-608 is a proprietary nafamostat formulation for direct IV infusion that will be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC) and acute pancreatitis.

 

 
 

 

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO® in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and several product candidates. The product candidates include: Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg), an investigational product in the U.S. being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings; two pre-filled, ready-to-use syringes of ephedrine and phenylephrine licensed for the U.S. from Aguettant; Niyad™, a regional anticoagulant for the extracorporeal circuit; and LTX-608, for the potential treatment of COVID-19, disseminated intravascular coagulation, acute respiratory distress syndrome and acute pancreatitis. DZUVEO and Zalviso are both approved products in Europe.

 

This release is intended for investors only. For additional information about AcelRx, please visit www.acelrx.com.

 

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the expected effect and scope of cost savings arising from our restructuring efforts, the potential extension of our cash runway, the expected benefits arising from potential partnerships with DSUVIA, the expected benefits arising from our recent acquisition of Lowell, potential near-term value-creating catalysts arising under our development pipeline, the expected market opportunity for our new product candidates in-licensed from Aguettant and/or acquired through the Lowell acquisition, our plans to file NDAs and other regulatory submissions for our new product candidates and the timing of such filings. These and any other forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking terminology such as "believe," "expect," “expected,” "anticipate," "may," "will," "should," "seek," "approximately," "intends," "plans," "estimates," “benefits,” or the negative of these words or other comparable terminology. The discussion of financial trends, strategy, plans or intentions may also include forward-looking statements, which are predictions, projections and other statements about future events that are based on current expectations and assumptions. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied by such statements, including:  (i) the risk that the restructuring of the Company could adversely affect our ability to successfully market DSUVIA in existing and in new and untested markets; (ii) risks relating to our ability to obtain regulatory approvals for the pre-filled syringe product candidates in-licensed from Aguettant; (iii) risks relating to our ability to successfully commercialize the pre-filled syringe product candidates in-licensed from Aguettant should we obtain such regulatory approvals; (iv) risks relating to our ability to obtain regulatory approvals for the nafamostat product candidates acquired from Lowell; (v) risks relating to our ability to obtain an emergency use authorization for Niyad; (vi) risks relating to our ability to successfully commercialize the nafamostat product candidates acquired from Lowell should we obtain regulatory approvals; (vii) risks relating to AcelRx’s product development activities diverting AcelRx management's attention from ongoing commercial business operations; (viii) risks related to the ability of AcelRx to implement its development plans, forecasts and other business expectations; and (ix) risks related to unexpected variations in market growth and demand for AcelRx's commercial and developmental products and technologies. Although it is not possible to predict or identify all such risks and uncertainties, they may include, but are not limited to, those described under the caption "Risk Factors" and elsewhere in AcelRx's annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the Securities and Exchange Commission (SEC) and any subsequent public filings. You are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date such statements were first made. To the degree financial information is included in this press release, it is in summary form only and must be considered in the context of the full details provided in AcelRx's most recent annual, quarterly or current report as filed or furnished with the SEC. AcelRx's SEC reports are available at www.acelrx.com under the "Investors" tab. Except to the extent required by law, AcelRx undertakes no obligation to publicly release the result of any revisions to these forward-looking statements to reflect new information, events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events. 

 

 

 

Investor Contacts:

 

AcelRx

Raffi Asadorian, CFO
650-216-3500
investors@acelrx.com

LifeSci Advisors

Kevin Gardner
LifeSci Advisors
617-283-2856
kgardner@lifesciadvisors.com

Chris Calabrese
LifeSci Advisors
917-680-5608
ccalabrese@lifesciadvisors.com
 

 

###

 

 
 

 

Selected Financial Data

(in thousands, except per share data)

(unaudited)

 

   

Three Months Ended

 
   

March 31

  
   

2022

    

2021

  

Statement of Comprehensive Loss Data

                
                 

Revenue:

                

Product sales

   $ 442     $ 451  

Contract and other collaboration

     -       60  

Total revenue

     442       511  
                 

Operating costs and expenses:

                

Cost of goods sold (1)

     784       1,040  

Research and development (1)

     1,315       969  

Selling, general and administrative (1)

     7,338       7,644  

Total operating costs and expenses

     9,437       9,653  

Loss from operations

     (8,995 )     (9,142 )
                 

Other income (expense):

                

Interest expense

     (390 )     (672 )

Interest income and other income (expense), net

     38       76  

Non-cash interest income on liability related to sale of future royalties

     673       782  

Total other income (expense)

     321       186  

Net loss

   $ (8,674 )   $ (8,956 )
                 

Basic and diluted net loss per common share

   $ (0.06 )   $ (0.08 )
                 

Shares used in computing basic and diluted net loss per common share

     145,624       113,257  
                 

(1) Includes the following non-cash depreciation and stock-based compensation expense:

                
                 

Cost of goods sold

   $ 67     $ 77  

Research and development

     260       180  

Selling, general and administrative

     721       1,049  

Total

   $ 1,048     $ 1,306  

 

   

March 31, 2022

    

December 31, 2021

  

Selected Balance Sheet Data

                

Cash, cash equivalents and investments

   $ 39,349     $ 51,630  

Total assets

     71,971       77,893  

Total liabilities

     110,244       113,786  

Total stockholders' deficit

     (38,273 )     (35,893 )

 

 
 

 

Reconciliation of Non-GAAP Financial Measures
(Operating Expenses less associated depreciation and stock-based compensation expense)

 

   

Three Months Ended

 
   

March 31

  
   

2022

    

2021

  
                 

Operating expenses (GAAP):

                

Research and development

   $ 1,315     $ 969  

Selling, general and administrative

     7,338       7,644  

Total operating expenses

     8,653       8,613  

Less depreciation and stock-based compensation expense

     981       1,229  

Operating expenses (non-GAAP)

   $ 7,672     $ 7,384  

 

 
 EX-101.SCH 3 acrx-20220516.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 acrx-20220516_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 acrx-20220516_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 acrx-20220516_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 acelrx01.jpg begin 644 acelrx01.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document And Entity Information
May 16, 2022
Document Information [Line Items]  
Entity, Registrant Name ACELRX PHARMACEUTICALS, INC.
Document, Type 8-K
Document, Period End Date May 16, 2022
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-35068
Entity, Tax Identification Number 41-2193603
Entity, Address, Address Line One 25821 Industrial Boulevard, Suite 400
Entity, Address, City or Town Hayward
Entity, Address, State or Province CA
Entity, Address, Postal Zip Code 94545
City Area Code 650
Local Phone Number 216-3500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ACRX
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001427925
XML 9 acrx20220513_8k_htm.xml IDEA: XBRL DOCUMENT 0001427925 2022-05-16 2022-05-16 false 0001427925 8-K 2022-05-16 ACELRX PHARMACEUTICALS, INC. DE 001-35068 41-2193603 25821 Industrial Boulevard, Suite 400 Hayward CA 94545 650 216-3500 false false false false Common Stock ACRX NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.acrx.com/20220516/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports acrx20220513_8k.htm acrx-20220516.xsd acrx-20220516_def.xml acrx-20220516_lab.xml acrx-20220516_pre.xml ex_376053.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "acrx20220513_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "acrx-20220516_def.xml" ] }, "inline": { "local": [ "acrx20220513_8k.htm" ] }, "labelLink": { "local": [ "acrx-20220516_lab.xml" ] }, "presentationLink": { "local": [ "acrx-20220516_pre.xml" ] }, "schema": { "local": [ "acrx-20220516.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "acrx", "nsuri": "http://www.acrx.com/20220516", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acrx20220513_8k.htm", "contextRef": "d20228K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.acrx.com/20220516/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acrx20220513_8k.htm", "contextRef": "d20228K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acrx.com/20220516/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001437749-22-012464-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-22-012464-xbrl.zip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end